The global preclinical imaging market was valued at USD 4.56 billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 4.36% from 2025 to 2030. This growth is primarily driven by rising investments and funding in research and development (RD), as well as ongoing technological advancements that are enabling the creation of sophisticated hybrid imaging systems. These innovations are playing a crucial role in enhancing the accuracy, speed, and efficiency of preclinical studies across pharmaceutical, biotechnology, and academic research institutions.

Preclinical research is revolutionizing the landscape of modern healthcare by enabling more precise and early-stage insights into disease mechanisms and treatment responses. Preclinical imaging technologies are especially valuable due to their ability to minimize biological variability, gather large volumes of detailed biological data, and reduce the number of animals used in experiments, in alignment with the 3R principles—Replacement, Reduction, and Refinement. This ethical and scientific approach is gaining widespread adoption, particularly as global research institutions focus on more humane and effective methodologies.

The expanding number of clinical research organizations (CROs) and pharmaceutical companies worldwide is also contributing significantly to the market's growth. These entities are increasingly investing in in-vivo imaging systems for drug development and toxicology studies, which require real-time visualization of biological processes at the molecular and cellular levels. As a result, the demand for advanced imaging platforms, including micro-PET, micro-MRI, micro-CT, and optical imaging systems, continues to rise.

The integration of artificial intelligence (AI) into preclinical imaging represents a transformative trend within the industry. AI-driven analytics tools are capable of managing and interpreting vast amounts of complex imaging data, enabling researchers to extract critical insights, enhance diagnostic accuracy, and expedite decision-making in preclinical trials. A notable development in this space occurred in May 2023, when Koninklijke Philips N.V. launched the Philips CT 3500. This high-throughput CT system is designed to meet the rigorous demands of mass screening programs and routine radiology workflows. Equipped with advanced image reconstruction technologies and workflow optimization features, the CT 3500 delivers high-quality, rapid imaging, empowering clinicians and researchers to enhance operational efficiency and diagnostic confidence even in high-volume settings.

Despite these advancements, the market faces challenges stemming from regulatory constraints on animal testing, driven by the increasing influence of animal welfare organizations. These restrictions are prompting a shift toward alternative research methodologies, including in-vitro testing, micro-dosing strategies, computer-simulated models, virtual drug testing, and the creation of comprehensive digital databases for experimental validation. While these alternatives are gaining traction, imaging modalities that offer non-invasive capabilities, such as magnetic resonance imaging (MRI) and computed tomography (CT), continue to see strong adoption. These systems allow for detailed, repeated assessments of biological systems without causing harm, making them ideal for longitudinal studies and further reinforcing their importance in the future of preclinical research.

Get a preview of the latest developments in the Preclinical Imaging Market? Download your FREE sample PDF copy today and explore key data and trends

Detailed Segmentation:

Product Insights

The optical imaging segment held the largest revenue share of 13.6% in 2024 owing to their wide usage in small animal imaging and new drug discovery projects. The growing adoption of optical preclinical imaging can be attributed to several factors. 

Application Insights

In terms of application, the research development segment captured the largest revenue share in 2024. The National Institutes of Health (NIH) conducts clinical research trials for numerous diseases and conditions, including Alzheimer’s disease, neurological disorders, allergies, cancer, and infectious diseases.

End-use Insights

The pharma and biotech companies segment captured the largest revenue share of 39.9% in 2024. The demand for pre-clinical imaging in biotech companies has been steadily increasing in recent years and is expected to continue growing in the coming years. T

Regional Insights

North America preclinical imaging market held the largest revenue share of 30.1% in 2024. This can be attributed to thewell-developed research infrastructure, the availability of skilled professionals, a large number of preclinical projects, and higher adoption rates of technically advanced devices in the region.

Key Preclinical Imaging Companies:

The following are the leading companies in the preclinical imaging market. These companies collectively hold the largest market share and dictate industry trends.

• Bruker Corporation,
• Siemens A.G.
• General Electric(GE)
• TriFoil Imaging
• PerkinElmer, Inc.
• FUJIFILM SonoSite
• Mediso Ltd.
• Agilent Technologies
• MILabs B.V.
• MR Solutions
• Molecubes

Recent Developments

• In April 2024, Spectral Instruments Imaging announced the launch of Aura 4.5, the newest iteration of its in vivo imaging software.
• In April 2023, Southern Scientific unveiled its role as the new distributor in the UK for Spectral Instruments Imaging, a leading manufacturer of preclinical in vivo imaging systems.
• In April 2023, Scintica, a distributor specializing in advanced preclinical research instrumentation, has announced a new collaboration with Bioemtech, a company focused on desktop SPECT, PET, and Optical scanners used in preclinical research. This partnership aims to broaden the accessibility of Bioemtech’s preclinical instruments to research scientists worldwide.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.